PIKA technology consists of synthetic biologic complex that is originated from our research and synthesized based on our proprietary GMP manufacturing technology. Through TLR3, RIG-I and MDA-5 signaling pathways, PIKA molecule can induce a prompt production of interferon, cytokines, chemokines and costimulatory factors. PIKA administration facilitates antigen cross-presentation by dendritic cells and augments CD4+ T-cell, CD8+ T-cell and natural killer-cell responses. When delivered with relevant antigen-based molecules, PIKA technology can be applied to the development of a new generation of antiviral vaccines, antiviral therapeutics and anticancer therapeutics, offering a promising platform for the development of a wide variety of novel biologics to improve treatments that are currently available and address unmet medical needs.
PIKA technology is originated from our research in a class of well-defined dsRNA molecules synthesized using our proprietary technology. Endosomal dsRNA can be recognized by TLR3 while cytosolic dsRNA can be sensed by the RIG-I-like receptor family which include RIG-I and MDA-5. Through TLR3, RIG-I and MDA-5 signaling, PIKA technology can induce a prompt production of interferon, cytokines, chemokines and costimulatory factors. The antiviral and antitumor effects of interferon have been well established. Production of type I interferon upon PIKA administration facilitates antigen cross-presentation by dendritic cells and augments CD4+ T-cell, CD8+ T-cell and natural killer-cell responses, which makes PIKA-based therapeutics suitable for both antiviral and antitumor applications.
Enabling development of diverse biotherapeutics based on TLR3, RIG-I and MDA-5 signaling pathways.
Enabling the disruption of tumor growth in multiple steps of the cancer-immunity cycle.
Enabling the activation of antitumor cell activity and the reduction of immunosuppressive effects of specific immune cells.
